Could cervical cancer be eliminated in 20 years?

By Kate Madden Yee, LabPulse.com contributing writer

February 10, 2020 -- If more women were screened for cervical cancer, it's possible that the incidence of the disease could be eliminated in the U.S. within the next two decades, according to a study published online February 10 in Lancet Public Health.

The findings suggest a way for the U.S. clinical community to actively respond to the World Health Organization's (WHO) 2018 charge to eliminate cervical cancer as a public health problem, wrote a team led by Emily Burger, PhD, of the Harvard T.H. Chan School of Public Health in Boston. The WHO's cervical cancer incidence target is four or fewer cases per 100,000 women-years.

"The [U.S.] is on track to eliminate cervical cancer as a public health problem in the next two to three decades," the group wrote. "Time to elimination could be expedited by 10-13 years by achieving higher screening coverage."

The U.S. is one of the first countries to have established prophylactic HPV vaccination protocols, but even so, screening practice remains subpar, with many women being underscreened and 14% never being screened at all, Burger and colleagues noted. The U.S. Preventive Services Task Force's (USPSTF) current screening guideline is a Pap smear every three years for women ages 21 to 65 years, or a combination of a Pap smear and HPV testing every five years for women ages 30 to 65 years who want to lengthen the screening interval.

"The effectiveness of screening is dependent on high, routine coverage and compliance to follow-up and treatment recommendations," the group wrote.

Because the gap between contracting HPV and developing cervical cancer can be decades, "understanding the cervical cancer burden in the [U.S.] in the future ... requires the use of mathematical simulation models," according to the researchers. Therefore, they used two cervical models that are part of the Cancer Intervention and Surveillance Modeling Network (CISNET) to estimate the incidence of the disease per 100,000 women-years and the number of cases averted between 2019 and 2100 if an aggressive screening and vaccination protocol were adopted.

The investigators found that increasing screening for the disease to 90% in 2020 could speed its elimination and avoid a mean of 1,400 to 2,088 additional cases between 2019 and 2100. This strategy would be more effective than increasing HPV vaccination coverage to 90% or vaccinating adults between the ages of 26 and 45 against HPV.

The study did have some limitations, including a lack of strategies for increasing screening and the fact that it did not take cost-effectiveness or health benefits beyond cervical cancer into account in its increased screening model.

"We assumed immediate changes to cervical cancer screening and vaccination beginning in the year 2020," the researchers wrote. "Any delay in achieving the coverage targets would delay the timing of elimination. Therefore, our projections can be considered to represent the earliest estimates of when the interventions could enable cervical cancer incidence rates in the [U.S.] to decrease below the WHO threshold of elimination."

Naveris blood test spots recurrence of HPV cancers
Molecular diagnostics firm Naveris is highlighting research published online February 5 in the Journal of Clinical Oncology that demonstrates...
Becton Dickinson files for Onclarity FDA approval in 11 more HPV types
Becton Dickinson has submitted a premarket approval filing with the U.S. Food and Drug Administration (FDA) for its Onclarity test for an expanded number...
Older women miss out on cervical cancer screening
U.S. surveys of women ages 45 to 65 show that cervical cancer screening rates are subpar, even though this type of cancer often occurs later in life,...
What will it take for home cervical cancer testing to take off?
Self-sampling by women for cervical cancer screening promises to be highly effective clinically, though practical hurdles remain in terms of implementation...
Test shows promise for improving HPV triage
A new test shows promise for second-line use in patients with a positive HPV result to reduce the number of unnecessary colposcopies and as a two-in-one...

Copyright © 2020 LabPulse.com

Last Updated np 2/10/2020 3:38:00 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email